Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Radium-223 Chloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

Next Previous
X
Search
Trial Profile

Radium-223 Chloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Radium 223 chloride (Primary)
  • Indications Bone metastases; Prostate cancer
  • Focus Expanded access; Therapeutic Use
  • Sponsors Bayer

    • Most Recent Events

    • 14 Sep 2015 Overall survival results will be presented at the 2015 European Cancer Congress, according to a Bayer media release.
    • 02 Jun 2015 Results of pain assessment in 182 patients with baseline pain scores presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 23 Feb 2015 According to a Bayer HealthCare Pharmaceuticals media release, data from this study will be presented at the 2015 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top